{"gene":"CD59","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":2023,"finding":"Cryo-EM structures of inhibited MAC precursors C5b8 and C5b9 reveal that CD59 binds the pore-forming β-hairpins of C8 to form an intermolecular β-sheet that prevents membrane perforation; while bound to C8, CD59 deflects cascading C9 β-hairpins, rerouting their trajectory into the membrane, which restricts structural transitions of subsequent C9 monomers and halts MAC polymerization.","method":"Cryo-electron microscopy, cellular lysis assays, molecular dynamics simulations","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM structures with functional validation and MD simulations in a single study","pmids":["36797260"],"is_preprint":false},{"year":1992,"finding":"CD59 binds specifically to the α-chain of C8 and to the C9b domain (residues within the 37-kDa thrombin fragment) of C9, but not to C5b6, C7, or C8β; binding occurs via protein-protein interaction (not via the GPI phospholipid moiety) and is detected only when C8/C9 are surface-adsorbed, suggesting a conformational change exposes the CD59 binding site.","method":"Radiolabeled (125I) CD59 binding assay with density gradient analysis, surface adsorption assay, ligand blotting after SDS-PAGE separation of C8 subunits, alpha-thrombin digestion of C9","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 — rigorous in vitro binding assay with multiple controls and subunit-level mapping","pmids":["1377690"],"is_preprint":false},{"year":2006,"finding":"A 6-residue sequence of human C9 spanning residues 365-371 constitutes the primary CD59 recognition domain; both C8α and C9 bind to a similar or overlapping hydrophobic pocket on CD59; docking models indicate C9 residues 365-371 interact with the hydrophobic pocket on CD59 previously identified by mutagenesis.","method":"Peptide screens, binding assays with synthetic peptides, functional complement lysis assays, computer modeling and docking studies","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal methods (biochemical assay + computational modeling) identifying the binding epitope","pmids":["16844690"],"is_preprint":false},{"year":1996,"finding":"Site-directed mutagenesis of CD59 reveals: disulfide bridges maintaining the three finger-like loops (Cys3-Cys26, Cys19-Cys39, Cys45-Cys63) are required for cell surface expression; the Cys64-Cys69 disulfide in the small loop is not required for expression and its removal increases function; the functional site involves residues around Tyr61 (Tyr61→Gly abrogates function); the Arg53 region is the major epitope for most anti-CD59 monoclonal antibodies.","method":"Site-directed mutagenesis of disulfide bridges and specific residues, cell surface expression assays, complement lysis functional assays, antibody binding assays","journal":"Blood Cells, Molecules & Diseases","confidence":"High","confidence_rationale":"Tier 1 — systematic mutagenesis with functional validation, identifying the active site","pmids":["9075580"],"is_preprint":false},{"year":2014,"finding":"CD59 in pancreatic β-cells functions as a regulator of insulin secretion: extracellular CD59 disrupts membrane rafts and moderately stimulates insulin secretion when removed, while intracellular CD59 is required for regulated exocytosis; CD59 physically interacts with exocytotic SNARE proteins VAMP2 and Syntaxin-1.","method":"TIRF imaging, co-immunoprecipitation, CD59 silencing (siRNA), PI-PLC cleavage of surface CD59","journal":"Cell Metabolism","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (TIRF imaging + Co-IP + knockdown), single lab but rigorous","pmids":["24726385"],"is_preprint":false},{"year":2022,"finding":"Alternative splicing of CD59 in human pancreatic β-cells produces non-GPI-anchored intracellular isoforms (IRIS-1 and IRIS-2) with unique C-terminal domains; these isoforms localize to the cytosol, colocalize with insulin granules, interact with SNARE proteins VAMP2 and SNAP25, and rescue insulin secretion in CD59-knockout cells. IRIS-1 expression is reduced by glucotoxicity and in human T2D islets.","method":"Alternative splicing characterization, Co-immunoprecipitation with VAMP2/SNAP25, TIRF imaging, CRISPR/Cas9 knockout, rescue experiments, isoform-specific antibodies","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 — reconstitution (rescue), Co-IP, and KO with specific phenotypic readout in one study","pmids":["35666870"],"is_preprint":false},{"year":2001,"finding":"CD59-deficient mice generated by gene targeting show spontaneous intravascular hemolysis and hemoglobinuria, with increased erythrocyte complement susceptibility in vitro and elevated reticulocyte counts and hemoglobin in plasma/urine, demonstrating that CD59 is required to protect erythrocytes from spontaneous MAC-mediated lysis in vivo.","method":"Gene targeting in ES cells, acidified serum lysis test, in vitro complement lysis assay, plasma/urine hemoglobin measurement, reticulocyte counts","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — clean genetic KO with multiple defined physiological phenotypes","pmids":["11435315"],"is_preprint":false},{"year":1992,"finding":"CD59 acts as a second ligand for the CD2 molecule on T cells: CHO cells transfected with human CD59 form rosettes with human T cells inhibitable by anti-CD59 and anti-CD2 antibodies; radiolabeled CD59 binds specifically to CD2-expressing CHO cells and this binding is blocked by unlabeled CD59 and anti-CD2 antibody; binding of CD59 to resting T cells induces CD2R epitope expression.","method":"Rosette formation assay with CHO transfectants, competitive binding assay with 125I-labeled CD59, antibody blocking studies","journal":"European Journal of Immunology","confidence":"High","confidence_rationale":"Tier 1–2 — direct binding assay with labeled protein + functional rosette assay + epitope induction","pmids":["1385156"],"is_preprint":false},{"year":1994,"finding":"CD59 co-stimulates CD58-dependent T cell activation: CD59-expressing CHO cells enhance CD58-dependent T cell proliferation and IL-2 secretion in the presence of suboptimal PHA or anti-CD2 antibodies; this co-stimulation requires N-glycosylation of CD59 at Asn18 and is dependent on co-expression of CD58.","method":"T cell proliferation assays and IL-2 secretion assays with CD59/CD58 CHO transfectants, paraformaldehyde fixation, N-glycosylation mutant analysis, antibody blocking","journal":"Journal of Immunology","confidence":"Medium","confidence_rationale":"Tier 2 — functional assay with transfectants and mutagenesis, single lab","pmids":["7521361"],"is_preprint":false},{"year":2014,"finding":"CD59-mediated signaling in Jurkat T cells is transmitted to the TCR/CD3 pathway through Lck: siRNA knockdown of Lck or LAT abolishes CD59-triggered Ca2+ signaling; physically linking Lck to CD3ζ completely abolishes CD59-triggered Ca2+ signaling while direct TCR/CD3 stimulation remains functional, placing Lck downstream of CD59 but upstream of TCR/CD3.","method":"Single-cell Ca2+ imaging, siRNA knockdown, TCR/CD3-deficient and overexpressing cell lines, co-patterning and FRAP experiments, flow cytometry","journal":"PloS One","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis via siRNA + dominant-negative approach, single lab","pmids":["24454946"],"is_preprint":false},{"year":1991,"finding":"Anti-CD59 and anti-CD55 monoclonal antibodies co-immunoprecipitate an 80-kDa glycoprotein from detergent lysates along with their respective antigens, and the CD59 immunoprecipitate contains a protein kinase activity, indicating that CD59 exists in noncovalent membrane complexes with this 80-kDa protein, CD55, glycolipids, and an associated kinase.","method":"Immunoprecipitation from detergent lysates, co-precipitation of associated proteins, protein kinase activity assay","journal":"Journal of Immunology","confidence":"Medium","confidence_rationale":"Tier 3 — single co-IP with kinase activity; foundational but limited mechanistic detail","pmids":["1715364"],"is_preprint":false},{"year":2006,"finding":"Expression of GPI-anchored CD59 on human target cells enhances NK cell-mediated cytotoxicity; this requires the GPI anchor for signaling (BiMP- and transmembrane-anchored CD59 do not enhance NK killing even when in lipid rafts); GPI-anchored CD59 mediates activation events (Ca2+ flux) upon crosslinking, whereas non-GPI forms do not; glycosylation is not required.","method":"NK cytotoxicity assays, CD59 transfection and membrane incorporation, GPI anchor variants, Ca2+ flux assays, antibody blocking","journal":"Journal of Immunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple forms of CD59 tested with orthogonal assays, single lab","pmids":["16493049"],"is_preprint":false},{"year":2006,"finding":"p53 regulates CD59 expression: two p53-responsive elements in the CD59 gene bind p53 in vitro; siRNA knockdown of p53 reduces CD59 protein expression ~6-fold in HeLa cells; acetylation status of p53 modulates CD59 expression in response to inflammatory cytokines.","method":"p53 binding assay (in vitro), siRNA knockdown of p53, Western blotting, complement lysis assay, cytokine treatment","journal":"Cancer Research","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro binding + genetic knockdown with protein-level readout, single lab","pmids":["16489052"],"is_preprint":false},{"year":1993,"finding":"CD59 expression on endothelial cells (EA.hy 926) is up-regulated ~3-fold by protein kinase C inducers PMA and calcium ionophore A23187, and by the PKA inducer dibutyryl-cAMP; this up-regulation occurs at the mRNA level and results in increased resistance to complement-mediated cell lysis.","method":"Flow cytometry, Northern blot analysis, complement-mediated lysis assay","journal":"European Journal of Immunology","confidence":"Medium","confidence_rationale":"Tier 2 — mRNA and protein level with functional consequence, single lab","pmids":["7691609"],"is_preprint":false},{"year":1993,"finding":"Enhanced CD59 (MIRL) expression induced by PMA in K562 cells is regulated at the transcriptional level; PMA-induced up-regulation of MIRL RNA and protein is abrogated by inhibitors of protein synthesis and transcription, consistent with PMA inducing a trans-acting protein that enhances MIRL gene transcription.","method":"Northern blot analysis, immunoprecipitation of metabolically labeled proteins, Western blot, inhibitors of transcription and protein synthesis","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — mRNA + protein assay with pharmacological inhibitors, single lab","pmids":["7687899"],"is_preprint":false},{"year":1997,"finding":"Glycosylation at Asn-16 of rat CD59 is not required for complement-inhibitory function: a glycosylation mutant lacking N-linked carbohydrate (reduced MW from ~20-28 kDa to ~12 kDa) retains full complement-inhibitory activity against all complement sources tested.","method":"Site-directed mutagenesis of N-glycosylation site, SDS-PAGE, CHO cell expression, complement lysis assay with multiple complement sources","journal":"Immunology","confidence":"Medium","confidence_rationale":"Tier 1 — mutagenesis with functional validation, single lab","pmids":["9176120"],"is_preprint":false},{"year":1996,"finding":"Overexpression of transfected CD59 in glomerular mesangial cells protects against both lytic and sublytic C5b-9 attack: CD59-transfected cells show marked resistance to complement lysis reversible by anti-CD59 antibody, and overexpressed CD59 suppresses superoxide production induced by sublytic C5b-9.","method":"FLAG-tagged CD59 expression vector, stable transfection, immunocytochemistry, Western blotting, complement-mediated lysis assay, superoxide production measurement","journal":"Kidney International","confidence":"Medium","confidence_rationale":"Tier 2 — overexpression with multiple functional readouts, single lab","pmids":["8807596"],"is_preprint":false},{"year":2005,"finding":"Glycation of CD59 on erythrocytes from hyperglycaemic (poorly controlled type 1 diabetes) individuals impairs its complement-inhibitory function in vivo: despite normal surface expression of CD59 by antibody staining, erythrocytes from hyperglycaemic subjects were more susceptible to complement lysis, and this susceptibility was entirely attributable to loss of functional CD59.","method":"Flow cytometry (CD59 surface expression), complement lysis assay, comparison of hyperglycaemic vs. normoglycaemic cohort","journal":"Immunology","confidence":"Medium","confidence_rationale":"Tier 2 — functional assay in patient-derived cells discriminating expression from function, single cohort","pmids":["15667573"],"is_preprint":false},{"year":1999,"finding":"A recombinant transmembrane form of CD59 (CD59-TM) expressed on GPI-anchor-deficient PNH B cells restores complement protection, demonstrating that the GPI anchor is not absolutely required for CD59 function, but alternative membrane attachment can support activity.","method":"Retroviral transduction, cell surface expression, PI-PLC cleavage assay (confirms lack of GPI), complement-mediated lysis assay","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — direct functional complementation in disease-relevant (PNH) cells, single lab","pmids":["7522635"],"is_preprint":false},{"year":2019,"finding":"Pancreatic cancer-educated macrophages (TAMs) upregulate CD59 on pancreatic cancer cells via the IL-6R/STAT3 signaling pathway, thereby protecting cancer cells from complement-dependent cytotoxicity; STAT3 inhibition abolishes macrophage-induced CD59 upregulation.","method":"Co-culture system (THP-1 macrophages + pancreatic cancer cells), RT-PCR, Western blot, immunofluorescence, CDC assay, RNA sequencing, STAT3 inhibitors, siRNA knockdown, antibody neutralization","journal":"Cell Death & Disease","confidence":"Medium","confidence_rationale":"Tier 2 — RNA-seq pathway identification confirmed by multiple orthogonal methods, single lab","pmids":["31685825"],"is_preprint":false},{"year":2018,"finding":"CD59 deficiency in esophageal squamous cell carcinoma cells reduces Src kinase phosphorylation (Y416), impairs DNA damage repair, exacerbates DNA damage after ionizing radiation, and causes G2/M arrest and cellular senescence; a Src inhibitor (saracatinib) phenocopies CD59 deficiency in radiosensitization.","method":"Lentiviral shRNA knockdown and overexpression, phospho-Src Western blot, γH2AX assay, cell cycle analysis, MTT proliferation assay, Src inhibitor treatment","journal":"Cell Death & Disease","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with mechanistic pathway (Src kinase) and inhibitor validation, single lab","pmids":["30166523"],"is_preprint":false},{"year":2010,"finding":"CD59 deficiency accelerates angiotensin II-induced abdominal aortic aneurysm in ApoE-null mice, while transgenic overexpression of human CD59 attenuates it; MAC directly induces MMP-2 and MMP-9 gene expression in vitro through AP-1 and NF-κB signaling pathways, defining the mechanistic link between MAC and aneurysm progression.","method":"CD59 knockout and transgenic mouse models, angiotensin II infusion model, MMP activity assays, phospho-c-Jun/c-Fos/IKK/p65 Western blots, in vitro MAC treatment with AP-1 and NF-κB pathway analysis","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 — genetic KO + transgenic + in vitro mechanistic pathway with multiple readouts","pmids":["20212283"],"is_preprint":false},{"year":2021,"finding":"CD59, as an integral component of the LecA-interacting Gb3-enriched membrane domain along with flotillins, facilitates Pseudomonas aeruginosa invasion; depletion of CD59 reduces invasiveness of P. aeruginosa PAO1 by ~50%.","method":"Pull-down and mass spectrometry, flow cytometry, siRNA depletion of CD59 and flotillins, bacterial invasion assay","journal":"Cellular and Molecular Life Sciences","confidence":"Medium","confidence_rationale":"Tier 2 — MS identification + knockdown with quantitative invasion phenotype, single lab","pmids":["33555391"],"is_preprint":false},{"year":2016,"finding":"Crystal structures of vaginolysin and intermedilysin complexed to CD59 reveal that CD59-responsive CDCs bind CD59 at different though overlapping sites; the CDC consensus undecapeptide proline (replacing the conserved tryptophan) acts as a selectivity switch ensuring CD59-dependent CDCs bind their protein receptor before cholesterol.","method":"X-ray crystallography, small-angle X-ray scattering, molecular dynamics simulations, binding studies","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 — crystal structures with functional validation by binding assays and MD simulations","pmids":["27499440"],"is_preprint":false},{"year":2016,"finding":"Intermedilysin (ILY) requires CD59 for specific coordination of monomers and to trigger collapse of an oligomeric prepore; Domain 2 movement relative to Domain 3 of ILY is essential for forming a late prepore intermediate that releases CD59, while cholesterol's role is limited to insertion of transmembrane segments.","method":"Biochemical assays, electron microscopy, atomic force microscopy, domain movement analysis","journal":"Scientific Reports","confidence":"High","confidence_rationale":"Tier 1 — structural EM + AFM + biochemical assays define mechanistic timeline","pmids":["27910935"],"is_preprint":false},{"year":2022,"finding":"EGFR/Wnt signaling induces β-catenin-mediated expression of lncRNA LINC00973, which sponges miR-150 (targeting CD59) and miR-216b (targeting CD55), resulting in CD59 upregulation that suppresses the complement system and blocks cytokine secretion required for CD8+ T cell activation in lung cancer.","method":"miRNA sponge mechanism characterization, LINC00973 promoter mutation, anti-CD55/CD59 antibody treatment, complement activation assays, CD8+ T cell activation assays, tumor growth experiments, EGFR/Wnt pathway inhibition","journal":"Nature Cancer","confidence":"Medium","confidence_rationale":"Tier 2 — multi-step pathway validated by promoter mutation and functional complement/T cell assays, single lab","pmids":["36271172"],"is_preprint":false},{"year":2012,"finding":"A homozygous missense mutation p.Cys89Tyr in CD59 causes loss of surface membrane localization: the mutated protein is present intracellularly in reduced amounts but is undetectable at the cell membrane by flow cytometry and Western blot, leading to chronic hemolysis and demyelinating polyneuropathy.","method":"Homozygosity mapping, exome sequencing, Sanger sequencing, flow cytometry for surface CD59 expression, Western blot","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — germline mutation with mechanistic demonstration of mislocalization, single family study","pmids":["23149847"],"is_preprint":false}],"current_model":"CD59 is a GPI-anchored membrane glycoprotein that inhibits MAC formation by binding the pore-forming β-hairpins of C8 (via its hydrophobic pocket centered on residues including Tyr61) to block membrane perforation and by deflecting cascading C9 monomers to prevent MAC polymerization; in addition, non-GPI-anchored intracellular splice isoforms (IRIS-1/IRIS-2) interact with SNARE proteins VAMP2 and SNAP25 to regulate insulin secretion in pancreatic β-cells, and its GPI-anchored surface form participates in T cell signaling through Lck and the TCR/CD3 pathway, as well as in lipid-raft-mediated host cell invasion and NK cell activation."},"narrative":{"teleology":[{"year":1991,"claim":"Establishing that CD59 exists in membrane signaling complexes: before this study it was unclear whether the small GPI-anchored protein participated in multiprotein assemblies; co-immunoprecipitation revealed CD59 associates with CD55, an 80-kDa glycoprotein, and a protein kinase, indicating it resides in organized membrane signaling domains.","evidence":"Co-immunoprecipitation from detergent lysates with kinase activity assay on human cells","pmids":["1715364"],"confidence":"Medium","gaps":["Identity of the 80-kDa co-precipitating protein unknown","No reciprocal pull-down or independent confirmation","Kinase identity not determined"]},{"year":1992,"claim":"Defining the molecular targets of CD59 within the MAC: it was unknown which complement components CD59 engaged; binding assays demonstrated direct protein–protein interaction with C8α and the C9b domain of C9 (but not C5b6, C7, or C8β), and showed binding requires a conformational change exposed upon surface adsorption.","evidence":"Radiolabeled (¹²⁵I) CD59 binding to purified complement proteins, ligand blotting, thrombin digestion mapping","pmids":["1377690"],"confidence":"High","gaps":["Structural basis of the conformational change not resolved","Stoichiometry of CD59:C8/C9 interaction unknown"]},{"year":1992,"claim":"Identifying CD59 as a second ligand for CD2 on T cells: beyond complement regulation, CD59 was shown to bind CD2 directly and induce CD2R epitope expression, establishing a complement-independent role in T cell adhesion and activation.","evidence":"Rosette formation with CD59-transfected CHO cells, competitive binding with ¹²⁵I-labeled CD59, antibody blocking","pmids":["1385156"],"confidence":"High","gaps":["Downstream signaling pathway from CD59-CD2 interaction not mapped","Physiological relevance in vivo not established"]},{"year":1993,"claim":"Demonstrating transcriptional regulation of CD59: CD59 expression was known to vary across cell types but how it was regulated was unclear; PMA, calcium ionophore, and cAMP were shown to upregulate CD59 mRNA and protein on endothelial and K562 cells, with PMA acting through a newly synthesized trans-acting factor.","evidence":"Northern blot, flow cytometry, complement lysis assay, transcription/translation inhibitor studies in endothelial and K562 cells","pmids":["7691609","7687899"],"confidence":"Medium","gaps":["Identity of the PMA-induced trans-acting factor unknown","Promoter elements mediating the response not mapped"]},{"year":1996,"claim":"Mapping the functional active site of CD59: systematic mutagenesis identified Tyr61 as critical for complement inhibition, defined required disulfide bridges for surface expression, and showed the Cys64-Cys69 disulfide constrains rather than enables function, establishing the structural determinants of activity.","evidence":"Site-directed mutagenesis of cysteines and Tyr61, cell-surface expression and complement lysis assays","pmids":["9075580"],"confidence":"High","gaps":["No high-resolution structure at this time to confirm spatial arrangement","Contribution of other residues in the hydrophobic pocket not tested"]},{"year":1999,"claim":"Demonstrating that a transmembrane-anchored CD59 can functionally replace the GPI-anchored form: this showed the GPI anchor is dispensable for complement protection per se, relevant to potential gene therapy for PNH.","evidence":"Retroviral transduction of transmembrane CD59 into GPI-anchor-deficient PNH B cells, complement lysis assay","pmids":["7522635"],"confidence":"Medium","gaps":["In vivo efficacy of transmembrane CD59 not tested","Whether transmembrane form participates in signaling not addressed"]},{"year":2001,"claim":"Validating CD59 as essential for erythrocyte protection in vivo: CD59 knockout mice exhibited spontaneous intravascular hemolysis and hemoglobinuria, confirming the non-redundant physiological requirement for MAC regulation on red blood cells.","evidence":"Gene-targeted CD59 knockout mice, acidified serum lysis, plasma/urine hemoglobin, reticulocyte counts","pmids":["11435315"],"confidence":"High","gaps":["Single-gene knockout may not model human PNH (which also lacks CD55)","Neurological phenotype not examined in mice"]},{"year":2006,"claim":"Pinpointing the C9 recognition epitope and shared binding pocket: a 6-residue C9 sequence (365–371) was identified as the primary CD59-binding domain, and both C8α and C9 were found to engage an overlapping hydrophobic pocket on CD59, explaining how one small protein blocks two sequential MAC components.","evidence":"Peptide screens, synthetic peptide binding/lysis assays, computational docking","pmids":["16844690"],"confidence":"High","gaps":["No co-crystal structure to confirm docking model","Whether CD59 can simultaneously contact C8 and C9 not resolved"]},{"year":2006,"claim":"Establishing CD59 as an enhancer of NK cell cytotoxicity in a GPI-anchor-dependent manner: GPI-anchored but not transmembrane or BiMP-anchored CD59 enhanced NK killing and triggered Ca²⁺ flux, revealing anchor-type specificity for signaling functions distinct from complement regulation.","evidence":"NK cytotoxicity assays, Ca²⁺ flux measurements, GPI vs. transmembrane CD59 variants on transfected cells","pmids":["16493049"],"confidence":"Medium","gaps":["NK receptor partner for CD59 not identified","Downstream signaling pathway in NK cells not mapped"]},{"year":2010,"claim":"Linking CD59 to vascular disease pathogenesis: CD59 deficiency accelerated angiotensin II–induced aortic aneurysm in ApoE-null mice while human CD59 transgenic expression was protective, with MAC shown to induce MMP-2/MMP-9 via AP-1 and NF-κB, establishing a mechanistic complement–MMP axis in aneurysm progression.","evidence":"CD59 KO and transgenic mice, Ang II infusion, MMP activity assays, pathway Western blots, in vitro MAC treatment","pmids":["20212283"],"confidence":"High","gaps":["Whether CD59 modulates aneurysm independently of MAC not tested","Applicability to human aortic disease not confirmed"]},{"year":2012,"claim":"Demonstrating that inherited CD59 deficiency causes a Mendelian disease: the p.Cys89Tyr mutation abolished surface localization of CD59, causing chronic hemolysis and demyelinating polyneuropathy and establishing CD59 deficiency as a discrete clinical entity.","evidence":"Homozygosity mapping, exome sequencing, flow cytometry, Western blot in a consanguineous family","pmids":["23149847"],"confidence":"Medium","gaps":["Single family; limited genotype–phenotype correlation","Mechanism of demyelination not elucidated"]},{"year":2014,"claim":"Uncovering a complement-independent role for CD59 in insulin secretion: intracellular CD59 was shown to be required for regulated exocytosis in β-cells and to physically interact with SNARE proteins VAMP2 and Syntaxin-1, establishing CD59 as a dual-function protein.","evidence":"TIRF imaging, co-immunoprecipitation, siRNA knockdown, PI-PLC cleavage in INS-1 and human β-cells","pmids":["24726385"],"confidence":"High","gaps":["Structural basis of CD59–SNARE interaction unknown","Whether complement-regulatory and exocytotic functions use distinct protein surfaces not determined"]},{"year":2014,"claim":"Mapping CD59 signaling through Lck to the TCR/CD3 pathway: CD59-triggered Ca²⁺ signals in T cells required Lck and LAT, and physically tethering Lck to CD3ζ abolished CD59 signaling while preserving TCR responses, placing CD59 upstream of Lck in a lipid-raft-initiated signaling cascade.","evidence":"Single-cell Ca²⁺ imaging, siRNA knockdown of Lck/LAT, Lck-CD3ζ chimera in Jurkat cells","pmids":["24454946"],"confidence":"Medium","gaps":["Mechanism by which GPI-anchored CD59 activates cytoplasmic Lck not resolved","Not confirmed in primary T cells"]},{"year":2016,"claim":"Revealing how bacterial cholesterol-dependent cytolysins (CDCs) exploit CD59: crystal structures of vaginolysin and intermedilysin bound to CD59 showed overlapping but distinct binding sites and identified a proline selectivity switch in the CDC undecapeptide that ensures CD59 engagement before cholesterol binding, defining CD59 as a pathogen receptor.","evidence":"X-ray crystallography, SAXS, MD simulations, binding assays for ILY and VLY–CD59 complexes","pmids":["27499440","27910935"],"confidence":"High","gaps":["Whether the CD59 site used by CDCs overlaps with the complement-inhibitory site not fully resolved","In vivo relevance to Gardnerella/Streptococcus infection not tested"]},{"year":2022,"claim":"Identifying alternatively spliced intracellular CD59 isoforms as dedicated exocytotic regulators: IRIS-1 and IRIS-2 lack the GPI signal, localize to the cytosol and insulin granules, interact with VAMP2 and SNAP25, and rescue insulin secretion in CD59-KO cells; IRIS-1 is reduced in T2D islets, linking CD59 splicing to diabetes pathogenesis.","evidence":"Isoform cloning, CRISPR KO and rescue, Co-IP, TIRF imaging, isoform-specific antibodies in human islets","pmids":["35666870"],"confidence":"High","gaps":["Structural basis of IRIS isoform–SNARE interaction not determined","Whether IRIS isoforms exist in non-β-cell secretory cells unknown"]},{"year":2023,"claim":"Resolving the atomic mechanism of MAC inhibition by CD59: cryo-EM structures of CD59-bound C5b8 and C5b9 showed CD59 forms an intermolecular β-sheet with C8 β-hairpins to block perforation and simultaneously deflects C9 β-hairpins to prevent MAC polymerization, unifying decades of biochemical data into a single structural framework.","evidence":"Cryo-EM structures at near-atomic resolution, complement lysis assays, MD simulations","pmids":["36797260"],"confidence":"High","gaps":["Dynamic on-rate kinetics of CD59 engagement with assembling MAC in live membranes not measured","Whether CD59 can disengage and recycle after blocking one MAC not addressed"]},{"year":null,"claim":"Key unresolved questions include how GPI-anchored CD59 transduces signals to cytoplasmic kinases (Lck, Src) without an intracellular domain, the structural basis of IRIS isoform–SNARE complex formation, and whether complement-regulatory and signaling/exocytotic functions of CD59 use overlapping or distinct protein surfaces.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structure of CD59–SNARE complex","Trans-membrane signaling mechanism for GPI-anchored CD59 unknown","Overlap between CDC-binding and complement-binding surfaces on CD59 not fully resolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,2,3,6,16,21]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1,6,11,18,26]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[5]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[4,5]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,2,6,21,25]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[9,11,20]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[4,5]}],"complexes":[],"partners":["C8A","C9","VAMP2","SNAP25","STX1A","CD2","LCK"],"other_free_text":[]},"mechanistic_narrative":"CD59 is a GPI-anchored complement regulatory glycoprotein that protects host cells from membrane attack complex (MAC)-mediated lysis and additionally functions in T cell co-stimulation, insulin exocytosis, and pathogen exploitation of lipid rafts. Cryo-EM structures show that CD59 binds the pore-forming β-hairpins of C8α via a hydrophobic pocket centered on Tyr61, forming an intermolecular β-sheet that prevents membrane perforation and deflects incoming C9 monomers to halt MAC polymerization [PMID:36797260, PMID:1377690, PMID:9075580]. Beyond complement regulation, alternatively spliced non-GPI-anchored intracellular isoforms (IRIS-1/IRIS-2) interact with SNARE proteins VAMP2 and SNAP25 to promote insulin granule exocytosis in pancreatic β-cells, with IRIS-1 expression reduced in type 2 diabetic islets [PMID:35666870, PMID:24726385]. Homozygous loss-of-function mutations in CD59 (e.g., p.Cys89Tyr) cause hereditary CD59 deficiency manifesting as chronic hemolysis and demyelinating polyneuropathy [PMID:23149847]."},"prefetch_data":{"uniprot":{"accession":"P13987","full_name":"CD59 glycoprotein","aliases":["1F5 antigen","20 kDa homologous restriction factor","HRF-20","HRF20","MAC-inhibitory protein","MAC-IP","MEM43 antigen","Membrane attack complex inhibition factor","MACIF","Membrane inhibitor of reactive lysis","MIRL","Protectin"],"length_aa":128,"mass_kda":14.2,"function":"Potent inhibitor of the complement membrane attack complex (MAC) action, which protects human cells from damage during complement activation (PubMed:11882685, PubMed:1698710, PubMed:2475111, PubMed:2475570, PubMed:2606909, PubMed:9053451). Acts by binding to the beta-haipins of C8 (C8A and C8B) components of the assembling MAC, forming an intermolecular beta-sheet that prevents incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore (PubMed:11882685, PubMed:1698710, PubMed:36797260) The soluble form from urine retains its specific complement binding activity, but exhibits greatly reduced ability to inhibit complement membrane attack complex (MAC) assembly on cell membranes","subcellular_location":"Cell membrane; Secreted","url":"https://www.uniprot.org/uniprotkb/P13987/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CD59","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CD59","total_profiled":1310},"omim":[{"mim_id":"621398","title":"CILIA- AND FLAGELLA-ASSOCIATED PROTEIN 100; CFAP100","url":"https://www.omim.org/entry/621398"},{"mim_id":"620781","title":"TRANSMEMBRANE PROTEIN 208; TMEM208","url":"https://www.omim.org/entry/620781"},{"mim_id":"619985","title":"GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 25; GPIBD25","url":"https://www.omim.org/entry/619985"},{"mim_id":"619979","title":"CHROMOSOME 18 OPEN READING FRAME 32; C18ORF32","url":"https://www.omim.org/entry/619979"},{"mim_id":"619812","title":"BLOOD GROUP, EMM SYSTEM; EMM","url":"https://www.omim.org/entry/619812"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Golgi apparatus","reliability":"Uncertain"},{"location":"Vesicles","reliability":"Uncertain"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CD59"},"hgnc":{"alias_symbol":["16.3A5","EJ16","EJ30","EL32","G344","p18-20"],"prev_symbol":["MIC11","MIN1","MSK21","MIN2","MIN3","MIRL","MACIF","HRF20"]},"alphafold":{"accession":"P13987","domains":[{"cath_id":"2.10.60.10","chopping":"24-118","consensus_level":"high","plddt":84.6687,"start":24,"end":118}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P13987","model_url":"https://alphafold.ebi.ac.uk/files/AF-P13987-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P13987-F1-predicted_aligned_error_v6.png","plddt_mean":79.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CD59","jax_strain_url":"https://www.jax.org/strain/search?query=CD59"},"sequence":{"accession":"P13987","fasta_url":"https://rest.uniprot.org/uniprotkb/P13987.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P13987/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P13987"}},"corpus_meta":[{"pmid":"9000677","id":"PMC_9000677","title":"Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage.","date":"1997","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/9000677","citation_count":260,"is_preprint":false},{"pmid":"7507156","id":"PMC_7507156","title":"Membrane defence against complement lysis: the structure and biological properties of CD59.","date":"1993","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/7507156","citation_count":142,"is_preprint":false},{"pmid":"11435315","id":"PMC_11435315","title":"Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria.","date":"2001","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11435315","citation_count":114,"is_preprint":false},{"pmid":"23149847","id":"PMC_23149847","title":"CD59 deficiency is associated with chronic hemolysis and childhood relapsing immune-mediated polyneuropathy.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23149847","citation_count":113,"is_preprint":false},{"pmid":"16884774","id":"PMC_16884774","title":"Alternative roles for CD59.","date":"2006","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16884774","citation_count":110,"is_preprint":false},{"pmid":"1377690","id":"PMC_1377690","title":"The human complement regulatory protein CD59 binds to the alpha-chain of C8 and to the \"b\"domain of C9.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1377690","citation_count":105,"is_preprint":false},{"pmid":"11027207","id":"PMC_11027207","title":"Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease.","date":"2000","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/11027207","citation_count":104,"is_preprint":false},{"pmid":"1385156","id":"PMC_1385156","title":"CD59 molecule: a second ligand for CD2 in T cell adhesion.","date":"1992","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1385156","citation_count":98,"is_preprint":false},{"pmid":"23474221","id":"PMC_23474221","title":"Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab.","date":"2013","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23474221","citation_count":91,"is_preprint":false},{"pmid":"17289551","id":"PMC_17289551","title":"The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias.","date":"2006","source":"Autoimmunity reviews","url":"https://pubmed.ncbi.nlm.nih.gov/17289551","citation_count":84,"is_preprint":false},{"pmid":"16844690","id":"PMC_16844690","title":"Defining the CD59-C9 binding interaction.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16844690","citation_count":83,"is_preprint":false},{"pmid":"1715364","id":"PMC_1715364","title":"Association of the CD59 and CD55 cell surface glycoproteins with other membrane molecules.","date":"1991","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1715364","citation_count":76,"is_preprint":false},{"pmid":"9014582","id":"PMC_9014582","title":"Complement in acute and chronic arthritides: assessment of C3c, C9, and protectin (CD59) in synovial membrane.","date":"1996","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/9014582","citation_count":76,"is_preprint":false},{"pmid":"9029105","id":"PMC_9029105","title":"Molecular cloning, chromosomal localization, expression, and functional characterization of the mouse analogue of human CD59.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9029105","citation_count":72,"is_preprint":false},{"pmid":"10931136","id":"PMC_10931136","title":"Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack.","date":"2000","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10931136","citation_count":70,"is_preprint":false},{"pmid":"11986227","id":"PMC_11986227","title":"Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11986227","citation_count":68,"is_preprint":false},{"pmid":"9808413","id":"PMC_9808413","title":"The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues.","date":"1998","source":"APMIS : acta pathologica, microbiologica, et immunologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/9808413","citation_count":68,"is_preprint":false},{"pmid":"24726385","id":"PMC_24726385","title":"The complement inhibitor CD59 regulates insulin secretion by modulating exocytotic events.","date":"2014","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24726385","citation_count":64,"is_preprint":false},{"pmid":"7528012","id":"PMC_7528012","title":"Molecular cloning of the rat analogue of human CD59: structural comparison with human CD59 and identification of a putative active site.","date":"1994","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/7528012","citation_count":63,"is_preprint":false},{"pmid":"36271172","id":"PMC_36271172","title":"Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade.","date":"2022","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36271172","citation_count":62,"is_preprint":false},{"pmid":"7530684","id":"PMC_7530684","title":"The expression of CD59 in normal human nervous tissue.","date":"1994","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7530684","citation_count":62,"is_preprint":false},{"pmid":"10946279","id":"PMC_10946279","title":"Identification and functional characterization of a new gene encoding the mouse terminal complement inhibitor CD59.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10946279","citation_count":59,"is_preprint":false},{"pmid":"9185710","id":"PMC_9185710","title":"Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer.","date":"1997","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9185710","citation_count":57,"is_preprint":false},{"pmid":"24915776","id":"PMC_24915776","title":"The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack.","date":"2014","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/24915776","citation_count":56,"is_preprint":false},{"pmid":"15693845","id":"PMC_15693845","title":"Transgenic pigs expressing human CD59, in combination with human membrane cofactor protein and human decay-accelerating factor.","date":"2005","source":"Xenotransplantation","url":"https://pubmed.ncbi.nlm.nih.gov/15693845","citation_count":56,"is_preprint":false},{"pmid":"36797260","id":"PMC_36797260","title":"Structural basis for membrane attack complex inhibition by CD59.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36797260","citation_count":55,"is_preprint":false},{"pmid":"28928834","id":"PMC_28928834","title":"CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity.","date":"2017","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/28928834","citation_count":54,"is_preprint":false},{"pmid":"15167611","id":"PMC_15167611","title":"Characterization of human CD55 and CD59 transgenic pigs and kidney xenotransplantation in the pig-to-baboon combination.","date":"2004","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/15167611","citation_count":54,"is_preprint":false},{"pmid":"20212283","id":"PMC_20212283","title":"Complement regulator CD59 protects against angiotensin II-induced abdominal aortic aneurysms in mice.","date":"2010","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/20212283","citation_count":54,"is_preprint":false},{"pmid":"22541656","id":"PMC_22541656","title":"Altered expression of CD46 and CD59 on leukocytes in neovascular age-related macular degeneration.","date":"2012","source":"American journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/22541656","citation_count":51,"is_preprint":false},{"pmid":"7517877","id":"PMC_7517877","title":"Expression and function of CD59 on colonic adenocarcinoma cells.","date":"1994","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7517877","citation_count":50,"is_preprint":false},{"pmid":"1704296","id":"PMC_1704296","title":"The complement-inhibiting protein, protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells.","date":"1991","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1704296","citation_count":49,"is_preprint":false},{"pmid":"7528832","id":"PMC_7528832","title":"Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells.","date":"1994","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/7528832","citation_count":49,"is_preprint":false},{"pmid":"1372164","id":"PMC_1372164","title":"Isolation and characterization of the complement-inhibiting protein CD59 antigen from platelet membranes.","date":"1992","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/1372164","citation_count":48,"is_preprint":false},{"pmid":"10375708","id":"PMC_10375708","title":"Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease.","date":"1999","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/10375708","citation_count":46,"is_preprint":false},{"pmid":"9664126","id":"PMC_9664126","title":"Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review).","date":"1998","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/9664126","citation_count":44,"is_preprint":false},{"pmid":"15389819","id":"PMC_15389819","title":"Transfer of functional prostasomal CD59 of metastatic prostatic cancer cell origin protects cells against complement attack.","date":"2005","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/15389819","citation_count":44,"is_preprint":false},{"pmid":"27568864","id":"PMC_27568864","title":"Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation.","date":"2016","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27568864","citation_count":43,"is_preprint":false},{"pmid":"7538183","id":"PMC_7538183","title":"Enhanced expression of decay accelerating factor and CD59/homologous restriction factor 20 on the colonic epithelium of ulcerative colitis.","date":"1995","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/7538183","citation_count":42,"is_preprint":false},{"pmid":"9075580","id":"PMC_9075580","title":"Structure-function relationships of the complement regulatory protein, CD59.","date":"1996","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/9075580","citation_count":42,"is_preprint":false},{"pmid":"7564108","id":"PMC_7564108","title":"Complement regulation in the rat glomerulus: Crry and CD59 regulate complement in glomerular mesangial and endothelial cells.","date":"1995","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/7564108","citation_count":42,"is_preprint":false},{"pmid":"24628556","id":"PMC_24628556","title":"Glycation of the complement regulatory protein CD59 is a novel biomarker for glucose handling in humans.","date":"2014","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24628556","citation_count":41,"is_preprint":false},{"pmid":"1383553","id":"PMC_1383553","title":"Gene structure of human CD59 and demonstration that discrete mRNAs are generated by alternative polyadenylation.","date":"1992","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1383553","citation_count":41,"is_preprint":false},{"pmid":"17080916","id":"PMC_17080916","title":"Diminished expression of complement regulatory proteins (CD55 and CD59) in lymphocytes from systemic lupus erythematosus patients with lymphopenia.","date":"2006","source":"Lupus","url":"https://pubmed.ncbi.nlm.nih.gov/17080916","citation_count":41,"is_preprint":false},{"pmid":"12880676","id":"PMC_12880676","title":"Deficiency of red cell bound CD55 and CD59 in patients with systemic lupus erythematosus.","date":"2003","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/12880676","citation_count":41,"is_preprint":false},{"pmid":"1378022","id":"PMC_1378022","title":"Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis.","date":"1992","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1378022","citation_count":40,"is_preprint":false},{"pmid":"24978917","id":"PMC_24978917","title":"Systematic immunohistochemical analysis of the expression of CD46, CD55, and CD59 in colon cancer.","date":"2014","source":"Archives of pathology & laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24978917","citation_count":39,"is_preprint":false},{"pmid":"28500075","id":"PMC_28500075","title":"Overexpression of Human CD55 and CD59 or Treatment with Human CD55 Protects against Renal Ischemia-Reperfusion Injury in Mice.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28500075","citation_count":39,"is_preprint":false},{"pmid":"28922377","id":"PMC_28922377","title":"C-reactive protein upregulates the whole blood expression of CD59 - an integrative analysis.","date":"2017","source":"PLoS computational biology","url":"https://pubmed.ncbi.nlm.nih.gov/28922377","citation_count":38,"is_preprint":false},{"pmid":"14712499","id":"PMC_14712499","title":"Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer.","date":"2004","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/14712499","citation_count":38,"is_preprint":false},{"pmid":"31685825","id":"PMC_31685825","title":"Pancreatic cancer-educated macrophages protect cancer cells from complement-dependent cytotoxicity by up-regulation of CD59.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31685825","citation_count":38,"is_preprint":false},{"pmid":"10086790","id":"PMC_10086790","title":"CD59-deficient blood cells and PIG-A gene abnormalities in Japanese patients with aplastic anaemia.","date":"1999","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/10086790","citation_count":37,"is_preprint":false},{"pmid":"9884334","id":"PMC_9884334","title":"Targeting of functional antibody-CD59 fusion proteins to a cell surface.","date":"1999","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/9884334","citation_count":36,"is_preprint":false},{"pmid":"30166523","id":"PMC_30166523","title":"CD59 is a potential biomarker of esophageal squamous cell carcinoma radioresistance by affecting DNA repair.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30166523","citation_count":36,"is_preprint":false},{"pmid":"7691609","id":"PMC_7691609","title":"Regulation of CD59 expression on the human endothelial cell line EA.hy 926.","date":"1993","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7691609","citation_count":35,"is_preprint":false},{"pmid":"20727519","id":"PMC_20727519","title":"Expression of CD55 and CD59 on peripheral blood cells from systemic lupus erythematosus (SLE) patients.","date":"2010","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20727519","citation_count":34,"is_preprint":false},{"pmid":"25716358","id":"PMC_25716358","title":"Early-onset chronic axonal neuropathy, strokes, and hemolysis: inherited CD59 deficiency.","date":"2015","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25716358","citation_count":34,"is_preprint":false},{"pmid":"10680700","id":"PMC_10680700","title":"Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies.","date":"2000","source":"European journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/10680700","citation_count":34,"is_preprint":false},{"pmid":"7521361","id":"PMC_7521361","title":"CD59 costimulation of T cell activation. CD58 dependence and requirement for glycosylation.","date":"1994","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7521361","citation_count":33,"is_preprint":false},{"pmid":"28476558","id":"PMC_28476558","title":"Low expression of complement inhibitory protein CD59 contributes to humoral autoimmunity against astrocytes.","date":"2017","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/28476558","citation_count":31,"is_preprint":false},{"pmid":"27159394","id":"PMC_27159394","title":"Cre-inducible human CD59 mediates rapid cell ablation after intermedilysin administration.","date":"2016","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/27159394","citation_count":31,"is_preprint":false},{"pmid":"29678656","id":"PMC_29678656","title":"Complement-Mediated Activation of the NLRP3 Inflammasome and Its Inhibition by AAV-Mediated Delivery of CD59 in a Model of Uveitis.","date":"2018","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29678656","citation_count":31,"is_preprint":false},{"pmid":"23835643","id":"PMC_23835643","title":"CD59 is overexpressed in human lung cancer and regulates apoptosis of human lung cancer cells.","date":"2013","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23835643","citation_count":31,"is_preprint":false},{"pmid":"27499440","id":"PMC_27499440","title":"Structural Basis for Receptor Recognition by the Human CD59-Responsive Cholesterol-Dependent Cytolysins.","date":"2016","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/27499440","citation_count":31,"is_preprint":false},{"pmid":"7694573","id":"PMC_7694573","title":"Expression of the glycosylphosphatidylinositol-linked complement-inhibiting protein CD59 antigen in insect cells using a baculovirus vector.","date":"1993","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/7694573","citation_count":31,"is_preprint":false},{"pmid":"1692709","id":"PMC_1692709","title":"Isolation and expression of the full-length cDNA encoding CD59 antigen of human lymphocytes.","date":"1990","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/1692709","citation_count":30,"is_preprint":false},{"pmid":"11720816","id":"PMC_11720816","title":"Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP.","date":"2001","source":"FEMS immunology and medical microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/11720816","citation_count":30,"is_preprint":false},{"pmid":"23690395","id":"PMC_23690395","title":"Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells.","date":"2013","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/23690395","citation_count":30,"is_preprint":false},{"pmid":"16271846","id":"PMC_16271846","title":"Effects of CD59 on antitumoral activities of phycocyanin from Spirulina platensis.","date":"2005","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/16271846","citation_count":29,"is_preprint":false},{"pmid":"7691713","id":"PMC_7691713","title":"Colocalization of the human CD59 gene to 11p13 with the MIC11 cell surface antigen.","date":"1993","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7691713","citation_count":29,"is_preprint":false},{"pmid":"12751952","id":"PMC_12751952","title":"Computerized video time-lapse (CVTL) analysis of the fate of giant cells produced by X-irradiating EJ30 human bladder carcinoma cells.","date":"2003","source":"Radiation research","url":"https://pubmed.ncbi.nlm.nih.gov/12751952","citation_count":28,"is_preprint":false},{"pmid":"23376460","id":"PMC_23376460","title":"Use of complement regulators, CD35, CD46, CD55, and CD59, on leukocytes as markers for diagnosis of viral and bacterial infections.","date":"2013","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23376460","citation_count":28,"is_preprint":false},{"pmid":"19254481","id":"PMC_19254481","title":"CD59 silencing via retrovirus-mediated RNA interference enhanced complement-mediated cell damage in ovary cancer.","date":"2009","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19254481","citation_count":27,"is_preprint":false},{"pmid":"8807596","id":"PMC_8807596","title":"Transfected CD59 protects mesangial cells from injury induced by antibody and complement.","date":"1996","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/8807596","citation_count":27,"is_preprint":false},{"pmid":"19424030","id":"PMC_19424030","title":"Upregulation of CD59: potential mechanism of accommodation in a large animal model.","date":"2009","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/19424030","citation_count":27,"is_preprint":false},{"pmid":"29447841","id":"PMC_29447841","title":"CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research.","date":"2018","source":"Journal of immunological methods","url":"https://pubmed.ncbi.nlm.nih.gov/29447841","citation_count":26,"is_preprint":false},{"pmid":"9176120","id":"PMC_9176120","title":"Expression of rat CD59: functional analysis confirms lack of species selectivity and reveals that glycosylation is not required for function.","date":"1997","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9176120","citation_count":26,"is_preprint":false},{"pmid":"15667573","id":"PMC_15667573","title":"Glycation of CD59 impairs complement regulation on erythrocytes from diabetic subjects.","date":"2005","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15667573","citation_count":26,"is_preprint":false},{"pmid":"22000275","id":"PMC_22000275","title":"The effects of CD59 gene as a target gene on breast cancer cells.","date":"2011","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22000275","citation_count":25,"is_preprint":false},{"pmid":"35666870","id":"PMC_35666870","title":"Alternative splicing encodes functional intracellular CD59 isoforms that mediate insulin secretion and are down-regulated in diabetic islets.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/35666870","citation_count":25,"is_preprint":false},{"pmid":"24454946","id":"PMC_24454946","title":"Lck mediates signal transmission from CD59 to the TCR/CD3 pathway in Jurkat T cells.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24454946","citation_count":25,"is_preprint":false},{"pmid":"33555391","id":"PMC_33555391","title":"The Gb3-enriched CD59/flotillin plasma membrane domain regulates host cell invasion by Pseudomonas aeruginosa.","date":"2021","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/33555391","citation_count":25,"is_preprint":false},{"pmid":"24205416","id":"PMC_24205416","title":"On the three-finger protein domain fold and CD59-like proteins in Schistosoma mansoni.","date":"2013","source":"PLoS neglected tropical diseases","url":"https://pubmed.ncbi.nlm.nih.gov/24205416","citation_count":25,"is_preprint":false},{"pmid":"24645827","id":"PMC_24645827","title":"Xenoantibody response to porcine islet cell transplantation using GTKO, CD55, CD59, and fucosyltransferase multiple transgenic donors.","date":"2014","source":"Xenotransplantation","url":"https://pubmed.ncbi.nlm.nih.gov/24645827","citation_count":25,"is_preprint":false},{"pmid":"31739586","id":"PMC_31739586","title":"Relating GPI-Anchored Ly6 Proteins uPAR and CD59 to Viral Infection.","date":"2019","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/31739586","citation_count":24,"is_preprint":false},{"pmid":"16493049","id":"PMC_16493049","title":"Expression of glycosylphosphatidylinositol-anchored CD59 on target cells enhances human NK cell-mediated cytotoxicity.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16493049","citation_count":24,"is_preprint":false},{"pmid":"16489052","id":"PMC_16489052","title":"p53 regulates cellular resistance to complement lysis through enhanced expression of CD59.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16489052","citation_count":24,"is_preprint":false},{"pmid":"10667419","id":"PMC_10667419","title":"Decreased expression of protectin (CD59) in gut epithelium in ulcerative colitis and Crohn's disease.","date":"1999","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10667419","citation_count":23,"is_preprint":false},{"pmid":"27910935","id":"PMC_27910935","title":"Disentangling the roles of cholesterol and CD59 in intermedilysin pore formation.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27910935","citation_count":22,"is_preprint":false},{"pmid":"18632654","id":"PMC_18632654","title":"Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18632654","citation_count":22,"is_preprint":false},{"pmid":"12452769","id":"PMC_12452769","title":"Computerized video time-lapse (CVTL) analysis of cell death kinetics in human bladder carcinoma cells (EJ30) X-irradiated in different phases of the cell cycle.","date":"2002","source":"Radiation research","url":"https://pubmed.ncbi.nlm.nih.gov/12452769","citation_count":20,"is_preprint":false},{"pmid":"18443552","id":"PMC_18443552","title":"Reduction of CD55 and/or CD59 in red blood cells of patients with HIV infection.","date":"2008","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/18443552","citation_count":20,"is_preprint":false},{"pmid":"24616098","id":"PMC_24616098","title":"Rapid degradation of the complement regulator, CD59, by a novel inhibitor.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24616098","citation_count":20,"is_preprint":false},{"pmid":"23707788","id":"PMC_23707788","title":"Zebrafish CD59 has both bacterial-binding and inhibiting activities.","date":"2013","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23707788","citation_count":20,"is_preprint":false},{"pmid":"7522635","id":"PMC_7522635","title":"Expression of recombinant transmembrane CD59 in paroxysmal nocturnal hemoglobinuria B cells confers resistance to human complement.","date":"1994","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7522635","citation_count":20,"is_preprint":false},{"pmid":"25725314","id":"PMC_25725314","title":"Expression of membrane complement regulators, CD46, CD55 and CD59, in mesothelial cells of patients on peritoneal dialysis therapy.","date":"2015","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25725314","citation_count":19,"is_preprint":false},{"pmid":"7481554","id":"PMC_7481554","title":"Down-regulation of CD59 (protectin) expression on human colorectal adenocarcinoma cell lines by levamisole.","date":"1995","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7481554","citation_count":19,"is_preprint":false},{"pmid":"28622911","id":"PMC_28622911","title":"Demyelination, strokes, and eculizumab: Lessons from the congenital CD59 gene mutations.","date":"2017","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28622911","citation_count":18,"is_preprint":false},{"pmid":"25976413","id":"PMC_25976413","title":"Sequestration of host-CD59 as potential immune evasion strategy of Trichomonas vaginalis.","date":"2015","source":"Acta tropica","url":"https://pubmed.ncbi.nlm.nih.gov/25976413","citation_count":18,"is_preprint":false},{"pmid":"7687899","id":"PMC_7687899","title":"Enhanced expression of the complement regulatory protein, membrane inhibitor of reactive lysis (CD59), is regulated at the level of transcription.","date":"1993","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7687899","citation_count":18,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48179,"output_tokens":6327,"usd":0.119721},"stage2":{"model":"claude-opus-4-6","input_tokens":10003,"output_tokens":3945,"usd":0.22296},"total_usd":0.342681,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2023,\n      \"finding\": \"Cryo-EM structures of inhibited MAC precursors C5b8 and C5b9 reveal that CD59 binds the pore-forming β-hairpins of C8 to form an intermolecular β-sheet that prevents membrane perforation; while bound to C8, CD59 deflects cascading C9 β-hairpins, rerouting their trajectory into the membrane, which restricts structural transitions of subsequent C9 monomers and halts MAC polymerization.\",\n      \"method\": \"Cryo-electron microscopy, cellular lysis assays, molecular dynamics simulations\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structures with functional validation and MD simulations in a single study\",\n      \"pmids\": [\"36797260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"CD59 binds specifically to the α-chain of C8 and to the C9b domain (residues within the 37-kDa thrombin fragment) of C9, but not to C5b6, C7, or C8β; binding occurs via protein-protein interaction (not via the GPI phospholipid moiety) and is detected only when C8/C9 are surface-adsorbed, suggesting a conformational change exposes the CD59 binding site.\",\n      \"method\": \"Radiolabeled (125I) CD59 binding assay with density gradient analysis, surface adsorption assay, ligand blotting after SDS-PAGE separation of C8 subunits, alpha-thrombin digestion of C9\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — rigorous in vitro binding assay with multiple controls and subunit-level mapping\",\n      \"pmids\": [\"1377690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"A 6-residue sequence of human C9 spanning residues 365-371 constitutes the primary CD59 recognition domain; both C8α and C9 bind to a similar or overlapping hydrophobic pocket on CD59; docking models indicate C9 residues 365-371 interact with the hydrophobic pocket on CD59 previously identified by mutagenesis.\",\n      \"method\": \"Peptide screens, binding assays with synthetic peptides, functional complement lysis assays, computer modeling and docking studies\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods (biochemical assay + computational modeling) identifying the binding epitope\",\n      \"pmids\": [\"16844690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Site-directed mutagenesis of CD59 reveals: disulfide bridges maintaining the three finger-like loops (Cys3-Cys26, Cys19-Cys39, Cys45-Cys63) are required for cell surface expression; the Cys64-Cys69 disulfide in the small loop is not required for expression and its removal increases function; the functional site involves residues around Tyr61 (Tyr61→Gly abrogates function); the Arg53 region is the major epitope for most anti-CD59 monoclonal antibodies.\",\n      \"method\": \"Site-directed mutagenesis of disulfide bridges and specific residues, cell surface expression assays, complement lysis functional assays, antibody binding assays\",\n      \"journal\": \"Blood Cells, Molecules & Diseases\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis with functional validation, identifying the active site\",\n      \"pmids\": [\"9075580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CD59 in pancreatic β-cells functions as a regulator of insulin secretion: extracellular CD59 disrupts membrane rafts and moderately stimulates insulin secretion when removed, while intracellular CD59 is required for regulated exocytosis; CD59 physically interacts with exocytotic SNARE proteins VAMP2 and Syntaxin-1.\",\n      \"method\": \"TIRF imaging, co-immunoprecipitation, CD59 silencing (siRNA), PI-PLC cleavage of surface CD59\",\n      \"journal\": \"Cell Metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (TIRF imaging + Co-IP + knockdown), single lab but rigorous\",\n      \"pmids\": [\"24726385\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Alternative splicing of CD59 in human pancreatic β-cells produces non-GPI-anchored intracellular isoforms (IRIS-1 and IRIS-2) with unique C-terminal domains; these isoforms localize to the cytosol, colocalize with insulin granules, interact with SNARE proteins VAMP2 and SNAP25, and rescue insulin secretion in CD59-knockout cells. IRIS-1 expression is reduced by glucotoxicity and in human T2D islets.\",\n      \"method\": \"Alternative splicing characterization, Co-immunoprecipitation with VAMP2/SNAP25, TIRF imaging, CRISPR/Cas9 knockout, rescue experiments, isoform-specific antibodies\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reconstitution (rescue), Co-IP, and KO with specific phenotypic readout in one study\",\n      \"pmids\": [\"35666870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CD59-deficient mice generated by gene targeting show spontaneous intravascular hemolysis and hemoglobinuria, with increased erythrocyte complement susceptibility in vitro and elevated reticulocyte counts and hemoglobin in plasma/urine, demonstrating that CD59 is required to protect erythrocytes from spontaneous MAC-mediated lysis in vivo.\",\n      \"method\": \"Gene targeting in ES cells, acidified serum lysis test, in vitro complement lysis assay, plasma/urine hemoglobin measurement, reticulocyte counts\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic KO with multiple defined physiological phenotypes\",\n      \"pmids\": [\"11435315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"CD59 acts as a second ligand for the CD2 molecule on T cells: CHO cells transfected with human CD59 form rosettes with human T cells inhibitable by anti-CD59 and anti-CD2 antibodies; radiolabeled CD59 binds specifically to CD2-expressing CHO cells and this binding is blocked by unlabeled CD59 and anti-CD2 antibody; binding of CD59 to resting T cells induces CD2R epitope expression.\",\n      \"method\": \"Rosette formation assay with CHO transfectants, competitive binding assay with 125I-labeled CD59, antibody blocking studies\",\n      \"journal\": \"European Journal of Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct binding assay with labeled protein + functional rosette assay + epitope induction\",\n      \"pmids\": [\"1385156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"CD59 co-stimulates CD58-dependent T cell activation: CD59-expressing CHO cells enhance CD58-dependent T cell proliferation and IL-2 secretion in the presence of suboptimal PHA or anti-CD2 antibodies; this co-stimulation requires N-glycosylation of CD59 at Asn18 and is dependent on co-expression of CD58.\",\n      \"method\": \"T cell proliferation assays and IL-2 secretion assays with CD59/CD58 CHO transfectants, paraformaldehyde fixation, N-glycosylation mutant analysis, antibody blocking\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional assay with transfectants and mutagenesis, single lab\",\n      \"pmids\": [\"7521361\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CD59-mediated signaling in Jurkat T cells is transmitted to the TCR/CD3 pathway through Lck: siRNA knockdown of Lck or LAT abolishes CD59-triggered Ca2+ signaling; physically linking Lck to CD3ζ completely abolishes CD59-triggered Ca2+ signaling while direct TCR/CD3 stimulation remains functional, placing Lck downstream of CD59 but upstream of TCR/CD3.\",\n      \"method\": \"Single-cell Ca2+ imaging, siRNA knockdown, TCR/CD3-deficient and overexpressing cell lines, co-patterning and FRAP experiments, flow cytometry\",\n      \"journal\": \"PloS One\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis via siRNA + dominant-negative approach, single lab\",\n      \"pmids\": [\"24454946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Anti-CD59 and anti-CD55 monoclonal antibodies co-immunoprecipitate an 80-kDa glycoprotein from detergent lysates along with their respective antigens, and the CD59 immunoprecipitate contains a protein kinase activity, indicating that CD59 exists in noncovalent membrane complexes with this 80-kDa protein, CD55, glycolipids, and an associated kinase.\",\n      \"method\": \"Immunoprecipitation from detergent lysates, co-precipitation of associated proteins, protein kinase activity assay\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single co-IP with kinase activity; foundational but limited mechanistic detail\",\n      \"pmids\": [\"1715364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Expression of GPI-anchored CD59 on human target cells enhances NK cell-mediated cytotoxicity; this requires the GPI anchor for signaling (BiMP- and transmembrane-anchored CD59 do not enhance NK killing even when in lipid rafts); GPI-anchored CD59 mediates activation events (Ca2+ flux) upon crosslinking, whereas non-GPI forms do not; glycosylation is not required.\",\n      \"method\": \"NK cytotoxicity assays, CD59 transfection and membrane incorporation, GPI anchor variants, Ca2+ flux assays, antibody blocking\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple forms of CD59 tested with orthogonal assays, single lab\",\n      \"pmids\": [\"16493049\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"p53 regulates CD59 expression: two p53-responsive elements in the CD59 gene bind p53 in vitro; siRNA knockdown of p53 reduces CD59 protein expression ~6-fold in HeLa cells; acetylation status of p53 modulates CD59 expression in response to inflammatory cytokines.\",\n      \"method\": \"p53 binding assay (in vitro), siRNA knockdown of p53, Western blotting, complement lysis assay, cytokine treatment\",\n      \"journal\": \"Cancer Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro binding + genetic knockdown with protein-level readout, single lab\",\n      \"pmids\": [\"16489052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"CD59 expression on endothelial cells (EA.hy 926) is up-regulated ~3-fold by protein kinase C inducers PMA and calcium ionophore A23187, and by the PKA inducer dibutyryl-cAMP; this up-regulation occurs at the mRNA level and results in increased resistance to complement-mediated cell lysis.\",\n      \"method\": \"Flow cytometry, Northern blot analysis, complement-mediated lysis assay\",\n      \"journal\": \"European Journal of Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mRNA and protein level with functional consequence, single lab\",\n      \"pmids\": [\"7691609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Enhanced CD59 (MIRL) expression induced by PMA in K562 cells is regulated at the transcriptional level; PMA-induced up-regulation of MIRL RNA and protein is abrogated by inhibitors of protein synthesis and transcription, consistent with PMA inducing a trans-acting protein that enhances MIRL gene transcription.\",\n      \"method\": \"Northern blot analysis, immunoprecipitation of metabolically labeled proteins, Western blot, inhibitors of transcription and protein synthesis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mRNA + protein assay with pharmacological inhibitors, single lab\",\n      \"pmids\": [\"7687899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Glycosylation at Asn-16 of rat CD59 is not required for complement-inhibitory function: a glycosylation mutant lacking N-linked carbohydrate (reduced MW from ~20-28 kDa to ~12 kDa) retains full complement-inhibitory activity against all complement sources tested.\",\n      \"method\": \"Site-directed mutagenesis of N-glycosylation site, SDS-PAGE, CHO cell expression, complement lysis assay with multiple complement sources\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with functional validation, single lab\",\n      \"pmids\": [\"9176120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Overexpression of transfected CD59 in glomerular mesangial cells protects against both lytic and sublytic C5b-9 attack: CD59-transfected cells show marked resistance to complement lysis reversible by anti-CD59 antibody, and overexpressed CD59 suppresses superoxide production induced by sublytic C5b-9.\",\n      \"method\": \"FLAG-tagged CD59 expression vector, stable transfection, immunocytochemistry, Western blotting, complement-mediated lysis assay, superoxide production measurement\",\n      \"journal\": \"Kidney International\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — overexpression with multiple functional readouts, single lab\",\n      \"pmids\": [\"8807596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Glycation of CD59 on erythrocytes from hyperglycaemic (poorly controlled type 1 diabetes) individuals impairs its complement-inhibitory function in vivo: despite normal surface expression of CD59 by antibody staining, erythrocytes from hyperglycaemic subjects were more susceptible to complement lysis, and this susceptibility was entirely attributable to loss of functional CD59.\",\n      \"method\": \"Flow cytometry (CD59 surface expression), complement lysis assay, comparison of hyperglycaemic vs. normoglycaemic cohort\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional assay in patient-derived cells discriminating expression from function, single cohort\",\n      \"pmids\": [\"15667573\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"A recombinant transmembrane form of CD59 (CD59-TM) expressed on GPI-anchor-deficient PNH B cells restores complement protection, demonstrating that the GPI anchor is not absolutely required for CD59 function, but alternative membrane attachment can support activity.\",\n      \"method\": \"Retroviral transduction, cell surface expression, PI-PLC cleavage assay (confirms lack of GPI), complement-mediated lysis assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct functional complementation in disease-relevant (PNH) cells, single lab\",\n      \"pmids\": [\"7522635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Pancreatic cancer-educated macrophages (TAMs) upregulate CD59 on pancreatic cancer cells via the IL-6R/STAT3 signaling pathway, thereby protecting cancer cells from complement-dependent cytotoxicity; STAT3 inhibition abolishes macrophage-induced CD59 upregulation.\",\n      \"method\": \"Co-culture system (THP-1 macrophages + pancreatic cancer cells), RT-PCR, Western blot, immunofluorescence, CDC assay, RNA sequencing, STAT3 inhibitors, siRNA knockdown, antibody neutralization\",\n      \"journal\": \"Cell Death & Disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RNA-seq pathway identification confirmed by multiple orthogonal methods, single lab\",\n      \"pmids\": [\"31685825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CD59 deficiency in esophageal squamous cell carcinoma cells reduces Src kinase phosphorylation (Y416), impairs DNA damage repair, exacerbates DNA damage after ionizing radiation, and causes G2/M arrest and cellular senescence; a Src inhibitor (saracatinib) phenocopies CD59 deficiency in radiosensitization.\",\n      \"method\": \"Lentiviral shRNA knockdown and overexpression, phospho-Src Western blot, γH2AX assay, cell cycle analysis, MTT proliferation assay, Src inhibitor treatment\",\n      \"journal\": \"Cell Death & Disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with mechanistic pathway (Src kinase) and inhibitor validation, single lab\",\n      \"pmids\": [\"30166523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CD59 deficiency accelerates angiotensin II-induced abdominal aortic aneurysm in ApoE-null mice, while transgenic overexpression of human CD59 attenuates it; MAC directly induces MMP-2 and MMP-9 gene expression in vitro through AP-1 and NF-κB signaling pathways, defining the mechanistic link between MAC and aneurysm progression.\",\n      \"method\": \"CD59 knockout and transgenic mouse models, angiotensin II infusion model, MMP activity assays, phospho-c-Jun/c-Fos/IKK/p65 Western blots, in vitro MAC treatment with AP-1 and NF-κB pathway analysis\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO + transgenic + in vitro mechanistic pathway with multiple readouts\",\n      \"pmids\": [\"20212283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CD59, as an integral component of the LecA-interacting Gb3-enriched membrane domain along with flotillins, facilitates Pseudomonas aeruginosa invasion; depletion of CD59 reduces invasiveness of P. aeruginosa PAO1 by ~50%.\",\n      \"method\": \"Pull-down and mass spectrometry, flow cytometry, siRNA depletion of CD59 and flotillins, bacterial invasion assay\",\n      \"journal\": \"Cellular and Molecular Life Sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — MS identification + knockdown with quantitative invasion phenotype, single lab\",\n      \"pmids\": [\"33555391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Crystal structures of vaginolysin and intermedilysin complexed to CD59 reveal that CD59-responsive CDCs bind CD59 at different though overlapping sites; the CDC consensus undecapeptide proline (replacing the conserved tryptophan) acts as a selectivity switch ensuring CD59-dependent CDCs bind their protein receptor before cholesterol.\",\n      \"method\": \"X-ray crystallography, small-angle X-ray scattering, molecular dynamics simulations, binding studies\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures with functional validation by binding assays and MD simulations\",\n      \"pmids\": [\"27499440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Intermedilysin (ILY) requires CD59 for specific coordination of monomers and to trigger collapse of an oligomeric prepore; Domain 2 movement relative to Domain 3 of ILY is essential for forming a late prepore intermediate that releases CD59, while cholesterol's role is limited to insertion of transmembrane segments.\",\n      \"method\": \"Biochemical assays, electron microscopy, atomic force microscopy, domain movement analysis\",\n      \"journal\": \"Scientific Reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structural EM + AFM + biochemical assays define mechanistic timeline\",\n      \"pmids\": [\"27910935\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"EGFR/Wnt signaling induces β-catenin-mediated expression of lncRNA LINC00973, which sponges miR-150 (targeting CD59) and miR-216b (targeting CD55), resulting in CD59 upregulation that suppresses the complement system and blocks cytokine secretion required for CD8+ T cell activation in lung cancer.\",\n      \"method\": \"miRNA sponge mechanism characterization, LINC00973 promoter mutation, anti-CD55/CD59 antibody treatment, complement activation assays, CD8+ T cell activation assays, tumor growth experiments, EGFR/Wnt pathway inhibition\",\n      \"journal\": \"Nature Cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multi-step pathway validated by promoter mutation and functional complement/T cell assays, single lab\",\n      \"pmids\": [\"36271172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"A homozygous missense mutation p.Cys89Tyr in CD59 causes loss of surface membrane localization: the mutated protein is present intracellularly in reduced amounts but is undetectable at the cell membrane by flow cytometry and Western blot, leading to chronic hemolysis and demyelinating polyneuropathy.\",\n      \"method\": \"Homozygosity mapping, exome sequencing, Sanger sequencing, flow cytometry for surface CD59 expression, Western blot\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — germline mutation with mechanistic demonstration of mislocalization, single family study\",\n      \"pmids\": [\"23149847\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CD59 is a GPI-anchored membrane glycoprotein that inhibits MAC formation by binding the pore-forming β-hairpins of C8 (via its hydrophobic pocket centered on residues including Tyr61) to block membrane perforation and by deflecting cascading C9 monomers to prevent MAC polymerization; in addition, non-GPI-anchored intracellular splice isoforms (IRIS-1/IRIS-2) interact with SNARE proteins VAMP2 and SNAP25 to regulate insulin secretion in pancreatic β-cells, and its GPI-anchored surface form participates in T cell signaling through Lck and the TCR/CD3 pathway, as well as in lipid-raft-mediated host cell invasion and NK cell activation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CD59 is a GPI-anchored complement regulatory glycoprotein that protects host cells from membrane attack complex (MAC)-mediated lysis and additionally functions in T cell co-stimulation, insulin exocytosis, and pathogen exploitation of lipid rafts. Cryo-EM structures show that CD59 binds the pore-forming β-hairpins of C8α via a hydrophobic pocket centered on Tyr61, forming an intermolecular β-sheet that prevents membrane perforation and deflects incoming C9 monomers to halt MAC polymerization [PMID:36797260, PMID:1377690, PMID:9075580]. Beyond complement regulation, alternatively spliced non-GPI-anchored intracellular isoforms (IRIS-1/IRIS-2) interact with SNARE proteins VAMP2 and SNAP25 to promote insulin granule exocytosis in pancreatic β-cells, with IRIS-1 expression reduced in type 2 diabetic islets [PMID:35666870, PMID:24726385]. Homozygous loss-of-function mutations in CD59 (e.g., p.Cys89Tyr) cause hereditary CD59 deficiency manifesting as chronic hemolysis and demyelinating polyneuropathy [PMID:23149847].\",\n  \"teleology\": [\n    {\n      \"year\": 1991,\n      \"claim\": \"Establishing that CD59 exists in membrane signaling complexes: before this study it was unclear whether the small GPI-anchored protein participated in multiprotein assemblies; co-immunoprecipitation revealed CD59 associates with CD55, an 80-kDa glycoprotein, and a protein kinase, indicating it resides in organized membrane signaling domains.\",\n      \"evidence\": \"Co-immunoprecipitation from detergent lysates with kinase activity assay on human cells\",\n      \"pmids\": [\"1715364\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the 80-kDa co-precipitating protein unknown\", \"No reciprocal pull-down or independent confirmation\", \"Kinase identity not determined\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Defining the molecular targets of CD59 within the MAC: it was unknown which complement components CD59 engaged; binding assays demonstrated direct protein–protein interaction with C8α and the C9b domain of C9 (but not C5b6, C7, or C8β), and showed binding requires a conformational change exposed upon surface adsorption.\",\n      \"evidence\": \"Radiolabeled (¹²⁵I) CD59 binding to purified complement proteins, ligand blotting, thrombin digestion mapping\",\n      \"pmids\": [\"1377690\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the conformational change not resolved\", \"Stoichiometry of CD59:C8/C9 interaction unknown\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Identifying CD59 as a second ligand for CD2 on T cells: beyond complement regulation, CD59 was shown to bind CD2 directly and induce CD2R epitope expression, establishing a complement-independent role in T cell adhesion and activation.\",\n      \"evidence\": \"Rosette formation with CD59-transfected CHO cells, competitive binding with ¹²⁵I-labeled CD59, antibody blocking\",\n      \"pmids\": [\"1385156\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling pathway from CD59-CD2 interaction not mapped\", \"Physiological relevance in vivo not established\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Demonstrating transcriptional regulation of CD59: CD59 expression was known to vary across cell types but how it was regulated was unclear; PMA, calcium ionophore, and cAMP were shown to upregulate CD59 mRNA and protein on endothelial and K562 cells, with PMA acting through a newly synthesized trans-acting factor.\",\n      \"evidence\": \"Northern blot, flow cytometry, complement lysis assay, transcription/translation inhibitor studies in endothelial and K562 cells\",\n      \"pmids\": [\"7691609\", \"7687899\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the PMA-induced trans-acting factor unknown\", \"Promoter elements mediating the response not mapped\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Mapping the functional active site of CD59: systematic mutagenesis identified Tyr61 as critical for complement inhibition, defined required disulfide bridges for surface expression, and showed the Cys64-Cys69 disulfide constrains rather than enables function, establishing the structural determinants of activity.\",\n      \"evidence\": \"Site-directed mutagenesis of cysteines and Tyr61, cell-surface expression and complement lysis assays\",\n      \"pmids\": [\"9075580\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure at this time to confirm spatial arrangement\", \"Contribution of other residues in the hydrophobic pocket not tested\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstrating that a transmembrane-anchored CD59 can functionally replace the GPI-anchored form: this showed the GPI anchor is dispensable for complement protection per se, relevant to potential gene therapy for PNH.\",\n      \"evidence\": \"Retroviral transduction of transmembrane CD59 into GPI-anchor-deficient PNH B cells, complement lysis assay\",\n      \"pmids\": [\"7522635\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo efficacy of transmembrane CD59 not tested\", \"Whether transmembrane form participates in signaling not addressed\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Validating CD59 as essential for erythrocyte protection in vivo: CD59 knockout mice exhibited spontaneous intravascular hemolysis and hemoglobinuria, confirming the non-redundant physiological requirement for MAC regulation on red blood cells.\",\n      \"evidence\": \"Gene-targeted CD59 knockout mice, acidified serum lysis, plasma/urine hemoglobin, reticulocyte counts\",\n      \"pmids\": [\"11435315\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single-gene knockout may not model human PNH (which also lacks CD55)\", \"Neurological phenotype not examined in mice\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Pinpointing the C9 recognition epitope and shared binding pocket: a 6-residue C9 sequence (365–371) was identified as the primary CD59-binding domain, and both C8α and C9 were found to engage an overlapping hydrophobic pocket on CD59, explaining how one small protein blocks two sequential MAC components.\",\n      \"evidence\": \"Peptide screens, synthetic peptide binding/lysis assays, computational docking\",\n      \"pmids\": [\"16844690\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No co-crystal structure to confirm docking model\", \"Whether CD59 can simultaneously contact C8 and C9 not resolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Establishing CD59 as an enhancer of NK cell cytotoxicity in a GPI-anchor-dependent manner: GPI-anchored but not transmembrane or BiMP-anchored CD59 enhanced NK killing and triggered Ca²⁺ flux, revealing anchor-type specificity for signaling functions distinct from complement regulation.\",\n      \"evidence\": \"NK cytotoxicity assays, Ca²⁺ flux measurements, GPI vs. transmembrane CD59 variants on transfected cells\",\n      \"pmids\": [\"16493049\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"NK receptor partner for CD59 not identified\", \"Downstream signaling pathway in NK cells not mapped\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Linking CD59 to vascular disease pathogenesis: CD59 deficiency accelerated angiotensin II–induced aortic aneurysm in ApoE-null mice while human CD59 transgenic expression was protective, with MAC shown to induce MMP-2/MMP-9 via AP-1 and NF-κB, establishing a mechanistic complement–MMP axis in aneurysm progression.\",\n      \"evidence\": \"CD59 KO and transgenic mice, Ang II infusion, MMP activity assays, pathway Western blots, in vitro MAC treatment\",\n      \"pmids\": [\"20212283\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CD59 modulates aneurysm independently of MAC not tested\", \"Applicability to human aortic disease not confirmed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrating that inherited CD59 deficiency causes a Mendelian disease: the p.Cys89Tyr mutation abolished surface localization of CD59, causing chronic hemolysis and demyelinating polyneuropathy and establishing CD59 deficiency as a discrete clinical entity.\",\n      \"evidence\": \"Homozygosity mapping, exome sequencing, flow cytometry, Western blot in a consanguineous family\",\n      \"pmids\": [\"23149847\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single family; limited genotype–phenotype correlation\", \"Mechanism of demyelination not elucidated\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Uncovering a complement-independent role for CD59 in insulin secretion: intracellular CD59 was shown to be required for regulated exocytosis in β-cells and to physically interact with SNARE proteins VAMP2 and Syntaxin-1, establishing CD59 as a dual-function protein.\",\n      \"evidence\": \"TIRF imaging, co-immunoprecipitation, siRNA knockdown, PI-PLC cleavage in INS-1 and human β-cells\",\n      \"pmids\": [\"24726385\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of CD59–SNARE interaction unknown\", \"Whether complement-regulatory and exocytotic functions use distinct protein surfaces not determined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Mapping CD59 signaling through Lck to the TCR/CD3 pathway: CD59-triggered Ca²⁺ signals in T cells required Lck and LAT, and physically tethering Lck to CD3ζ abolished CD59 signaling while preserving TCR responses, placing CD59 upstream of Lck in a lipid-raft-initiated signaling cascade.\",\n      \"evidence\": \"Single-cell Ca²⁺ imaging, siRNA knockdown of Lck/LAT, Lck-CD3ζ chimera in Jurkat cells\",\n      \"pmids\": [\"24454946\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which GPI-anchored CD59 activates cytoplasmic Lck not resolved\", \"Not confirmed in primary T cells\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Revealing how bacterial cholesterol-dependent cytolysins (CDCs) exploit CD59: crystal structures of vaginolysin and intermedilysin bound to CD59 showed overlapping but distinct binding sites and identified a proline selectivity switch in the CDC undecapeptide that ensures CD59 engagement before cholesterol binding, defining CD59 as a pathogen receptor.\",\n      \"evidence\": \"X-ray crystallography, SAXS, MD simulations, binding assays for ILY and VLY–CD59 complexes\",\n      \"pmids\": [\"27499440\", \"27910935\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the CD59 site used by CDCs overlaps with the complement-inhibitory site not fully resolved\", \"In vivo relevance to Gardnerella/Streptococcus infection not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identifying alternatively spliced intracellular CD59 isoforms as dedicated exocytotic regulators: IRIS-1 and IRIS-2 lack the GPI signal, localize to the cytosol and insulin granules, interact with VAMP2 and SNAP25, and rescue insulin secretion in CD59-KO cells; IRIS-1 is reduced in T2D islets, linking CD59 splicing to diabetes pathogenesis.\",\n      \"evidence\": \"Isoform cloning, CRISPR KO and rescue, Co-IP, TIRF imaging, isoform-specific antibodies in human islets\",\n      \"pmids\": [\"35666870\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of IRIS isoform–SNARE interaction not determined\", \"Whether IRIS isoforms exist in non-β-cell secretory cells unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Resolving the atomic mechanism of MAC inhibition by CD59: cryo-EM structures of CD59-bound C5b8 and C5b9 showed CD59 forms an intermolecular β-sheet with C8 β-hairpins to block perforation and simultaneously deflects C9 β-hairpins to prevent MAC polymerization, unifying decades of biochemical data into a single structural framework.\",\n      \"evidence\": \"Cryo-EM structures at near-atomic resolution, complement lysis assays, MD simulations\",\n      \"pmids\": [\"36797260\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dynamic on-rate kinetics of CD59 engagement with assembling MAC in live membranes not measured\", \"Whether CD59 can disengage and recycle after blocking one MAC not addressed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include how GPI-anchored CD59 transduces signals to cytoplasmic kinases (Lck, Src) without an intracellular domain, the structural basis of IRIS isoform–SNARE complex formation, and whether complement-regulatory and signaling/exocytotic functions of CD59 use overlapping or distinct protein surfaces.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structure of CD59–SNARE complex\", \"Trans-membrane signaling mechanism for GPI-anchored CD59 unknown\", \"Overlap between CDC-binding and complement-binding surfaces on CD59 not fully resolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 2, 3, 6, 16, 21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 6, 11, 18, 26]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [4, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 2, 6, 21, 25]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [9, 11, 20]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [4, 5]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"C8A\",\n      \"C9\",\n      \"VAMP2\",\n      \"SNAP25\",\n      \"STX1A\",\n      \"CD2\",\n      \"LCK\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}